Imagion Biosystems Ltd. (IBX) Price & Analysis

Q: What was Imagion Biosystems Ltd.’s price range in the past 12 months?

Imagion Biosystems Ltd. lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.

Q: What is Imagion Biosystems Ltd.’s market cap?

Imagion Biosystems Ltd.’s market cap is AU$10.79M.

Q: When is Imagion Biosystems Ltd.’s upcoming earnings report date?

Imagion Biosystems Ltd.’s upcoming earnings report date is Feb 26, 2026 which is in 8 days.

Q: How were Imagion Biosystems Ltd.’s earnings last quarter?

Imagion Biosystems Ltd. released its earnings results on Aug 27, 2025. The company reported -AU$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.008.

Q: Is Imagion Biosystems Ltd. overvalued?

According to Wall Street analysts Imagion Biosystems Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Imagion Biosystems Ltd. pay dividends?

Imagion Biosystems Ltd. does not currently pay dividends.

Q: What is Imagion Biosystems Ltd.’s EPS estimate?

Imagion Biosystems Ltd.’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Imagion Biosystems Ltd. have?

Imagion Biosystems Ltd. has 490,590,240 shares outstanding.

Q: What happened to Imagion Biosystems Ltd.’s price movement after its last earnings report?

Imagion Biosystems Ltd. reported an EPS of -AU$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Q: Which hedge fund is a major shareholder of Imagion Biosystems Ltd.?

Currently, no hedge funds are holding shares in AU:IBX

Compare

17 Followers

IBX Stock Chart & Stats

AU$0.03

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.03

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.06

Previous CloseN/A

Volume347.18K

Average Volume (3M)16.05M

Market Cap

AU$10.79M

Enterprise ValueAU$7.72M

Total Cash (Recent Filing)AU$883.57K

Total Debt (Recent Filing)AU$3.30M

Price to Earnings (P/E)―

Beta0.73

Next Earnings

Feb 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding490,590,240

10 Day Avg. Volume7,347,790

30 Day Avg. Volume16,053,124

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)-0.45

Price to Sales (P/S)0.39

P/FCF Ratio-0.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthNearly doubling revenue period-over-period indicates meaningful demand and adoption of the imaging platform. Durable top-line expansion supports scale economics, funds ongoing R&D and partnership talks, and creates a foundation to improve unit economics if revenue growth continues.

Improving Gross MarginMaterial improvement in gross profit margin signals improving product economics or pricing power. Sustained margin gains, combined with scale, can absorb fixed R&D and SG&A costs and materially shorten the path to sustainable operating profitability as the business grows.

Liquidity CushionOn-hand cash reserves provide a runway to advance clinical programs and commercialization steps over multiple quarters. This liquidity supports execution on structural milestones that can de-risk the business before significant additional financing is required.

Bears Say

Negative EquityNegative equity reflects cumulative losses exceeding net assets and indicates structural balance-sheet weakness. It constrains borrowing capacity, raises the likelihood of dilutive equity raises, and limits strategic flexibility to invest in commercialization without costly recapitalization.

Negative Operating Cash FlowPersistent negative operating cash flow shows the company cannot currently fund operations from core activities. Continued cash burn makes the business dependent on external financing, increasing dilution risk and creating execution uncertainty if funding access tightens.

Persistent Losses & Margin PressureOngoing net losses and negative EBIT margins indicate core operations are not yet profitable. Without converting strong revenue growth into positive operating margins, the company faces chronic loss dynamics that may force structural cost cuts or inhibit scalable commercialization.

Imagion Biosystems Ltd. News

Imagion Biosystems Files IND with FDA for Phase 2 MagSense HER2 Breast Cancer Trial

Imagion Biosystems Ltd. ( ($AU:IBX) ) has issued an announcement. Imagion Biosystems has submitted its first Investigational New...

17d ago

IBX

Imagion Advances MagSense HER2 Program Toward FDA IND and Bolsters US Leadership

Imagion Biosystems Ltd. ( ($AU:IBX) ) has shared an update. Imagion Biosystems has completed manufacturing and independent analytical...

21d ago

IBX

Imagion Biosystems Issues New Shares on Mercer Note Conversion, Flags Imminent HER2+ Trial Filing

An update from Imagion Biosystems Ltd. ( ($AU:IBX) ) is now available. Imagion Biosystems has issued 3,048,484 new...

1M ago

IBX

Imagion Biosystems Seeks ASX Quotation for 3.0 Million New Shares

An update from Imagion Biosystems Ltd. ( ($AU:IBX) ) is now available. Imagion Biosystems Limited has applied to...

1M ago

IBX

Imagion Biosystems Extinguishes First Mercer Tranche and Restructures Second Convertible Note

Imagion Biosystems Ltd. ( ($AU:IBX) ) has issued an announcement. Imagion Biosystems has completed the conversion of the...

1M ago

IBX

Imagion Biosystems Director Reshapes Equity Holdings With Share Acquisition and Rights Lapse

Imagion Biosystems Ltd. ( ($AU:IBX) ) has shared an update. Imagion Biosystems has disclosed a change in director...

1M ago

IBX

Imagion Biosystems Issues New Shares on Vesting of Performance Rights, Reaffirms Imminent HER2+ FDA Filing

Imagion Biosystems Ltd. ( ($AU:IBX) ) just unveiled an announcement. Imagion Biosystems has issued 1.4 million fully paid...

1M ago

IBX

Imagion Biosystems Seeks ASX Quotation for 1.4 Million New Shares

Imagion Biosystems Ltd. ( ($AU:IBX) ) just unveiled an announcement. Imagion Biosystems Limited has applied to the ASX...

1M ago

IBX

Imagion Biosystems Updates Securities Trading Policy

The latest announcement is out from Imagion Biosystems Ltd. ( ($AU:IBX) ). Imagion Biosystems announced an update to...

2M ago

IBX

Imagion Biosystems Issues New Shares to Support Cancer Detection Technology

Imagion Biosystems Ltd. ( ($AU:IBX) ) just unveiled an announcement. Imagion Biosystems has issued 8 million new ordinary...

2M ago

IBX

IBX FAQ

What was Imagion Biosystems Ltd.’s price range in the past 12 months?

Imagion Biosystems Ltd. lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.

What is Imagion Biosystems Ltd.’s market cap?

Imagion Biosystems Ltd.’s market cap is AU$10.79M.

When is Imagion Biosystems Ltd.’s upcoming earnings report date?

Imagion Biosystems Ltd.’s upcoming earnings report date is Feb 26, 2026 which is in 8 days.

How were Imagion Biosystems Ltd.’s earnings last quarter?

Imagion Biosystems Ltd. released its earnings results on Aug 27, 2025. The company reported -AU$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.008.

Is Imagion Biosystems Ltd. overvalued?

According to Wall Street analysts Imagion Biosystems Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Imagion Biosystems Ltd. pay dividends?

Imagion Biosystems Ltd. does not currently pay dividends.

What is Imagion Biosystems Ltd.’s EPS estimate?

Imagion Biosystems Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Imagion Biosystems Ltd. have?

Imagion Biosystems Ltd. has 490,590,240 shares outstanding.

What happened to Imagion Biosystems Ltd.’s price movement after its last earnings report?

Imagion Biosystems Ltd. reported an EPS of -AU$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Imagion Biosystems Ltd.?

Currently, no hedge funds are holding shares in AU:IBX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Imagion Biosystems Ltd. Stock Smart Score

Neutral

Blogger Sentiment

Bullish

AU:IBX Sentiment 90%
Sector Average 69%

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

78.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Imagion Biosystems Ltd.

Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.